The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical evaluation of cisplatin sensitivity germ line polymorphisms in neoadjuvant chemotherapy (NAC) for urothelial cancer (UC).
Peter H. O'Donnell
No relevant relationships to disclose
Ilana Rebecca Garcia-Grossman
No relevant relationships to disclose
Hongyuan Cao
No relevant relationships to disclose
Irina Ostrovnaya
No relevant relationships to disclose
Elizabeth R. Plimack
No relevant relationships to disclose
Kelly Lynn Stratton
No relevant relationships to disclose
Christopher Manschreck
No relevant relationships to disclose
Norm D. Smith
No relevant relationships to disclose
Gary D. Steinberg
No relevant relationships to disclose
Vijai Joseph
No relevant relationships to disclose
Kenneth Offit
No relevant relationships to disclose
Walter Michael Stadler
No relevant relationships to disclose
Dean F. Bajorin
No relevant relationships to disclose